Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center (MSK)

Status: Enrolling

Conditions: Neuroendocrine Tumors

Treatments: Diagnostic Test: positron emission tomography (PET) scans

Study type: Observational

Funder types: Other

Identifiers

NCT06448208

24-100

Details and patient eligibility

About

People with neuroendocrine cancer typically have imaging scans before and after treatment, including positron emission tomography (PET) scans. The scans are analyzed using a set of criteria that describes how the disease has responded to treatment. The purpose of this study is to establish new criteria for doctors to use when evaluating these PET scans. Researchers are testing whether these new criteria are useful for predicting whether a person's cancer gets better, gets worse, or stays the same. Researchers will also compare these new criteria to the current standard criteria for evaluating imaging scans.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Subjects affected by histologically proven, somatostatin-receptor positive, metastatic or inoperable well-differentiated G1, G2 or G3 neuroendocrine tumors (NETs) candidate to receive PRRT with 177Lu-DOTATATE per standard of care.

Inclusion Criteria:

1. Histologically proven or cytologically confirmed, metastatic or inoperable NETs
2. Measurable disease as defined by RECIST 1.1.
3. Overexpression of somatostatin receptors of the target lesions at somatostatin receptor imaging (68Ga-DOTATATE or 64Cu-DOTATATE PET/CT) with SUV of lesions greater than normal liver at least in 1 metastasis.

Exclusion Criteria:

1. Neuroendocrine Carcinoma), small and large cell type; MIxed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN).
2. Presence of somatostatin receptor negative lesions.

Trial design

50 participants in 1 patient group

People With Neuroendocrine Tumors having a PET/CT or MRI

Description:

This is a non-interventional observational study of imaging.

Treatment:

Diagnostic Test: positron emission tomography (PET) scans